文献速递临床试验与 GCP

急性脑损伤患者限制性与开放性输血策略比较:TRAIN随机临床试验

Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

TRAIN多中心3期随机试验纳入850例急性脑损伤贫血患者,比较开放性(血红蛋白<9 g/dL触发输血)与限制性(<7 g/dL触发)策略;180天不良神经结局开放性组62.6% vs 限制性组72.6%,绝对差异-10.0%(95%CI -16.5%至-3.6%),调整相对危险度0.86(95%CI 0.79-0.94;P=0.002)。

要点

  • 开放性输血策略组180天不良神经结局发生率低于限制性策略组。
  • 开放性组脑缺血事件8.8% vs 限制性组13.5%(相对危险度0.65,95%CI 0.44-0.97)。
  • 两组输血量中位数分别为2单位(IQR 1-3)与0单位(IQR 0-1)。

核心结论

  • 急性脑损伤合并贫血患者随机接受开放性输血策略者,发生不良神经结局的可能性低于限制性策略者。

研究设计与样本

  • 多中心、3期、平行组、研究者发起、实用性、开放标签随机临床试验,在22个国家72个重症监护病房开展。
  • 纳入创伤性脑损伤、动脉瘤性蛛网膜下腔出血或脑出血患者,伤后10天内血红蛋白低于9 g/dL,且预计重症监护病房停留至少72小时。
  • 2017年9月1日至2022年12月31日入组,末次随访日期为2023年6月30日。
  • 850例患者随机分为开放性策略组(血红蛋白<9 g/dL触发输血,n=408)或限制性策略组(血红蛋白<7 g/dL触发输血,n=442),干预持续28天。

主要发现

  • 完成试验的820例患者平均年龄51岁,女性376例(45.9%);806例有主要结局数据,开放性策略组393例,限制性策略组413例。
  • 开放性策略组输血量中位数2单位(IQR 1-3),限制性策略组0单位(IQR 0-1),绝对平均差异1.0单位(95%CI 0.87-1.12单位)。
  • 随机化后180天,开放性策略组246例(62.6%)发生不良神经结局,限制性策略组300例(72.6%),绝对差异-10.0%(95%CI -16.5%至-3.6%),调整相对危险度0.86(95%CI 0.79-0.94;P=0.002)。
  • 开放性策略组397例中35例(8.8%)发生至少1次脑缺血事件,限制性策略组423例中57例(13.5%),相对危险度0.65(95%CI 0.44-0.97)。
  • 输血阈值对180天神经结局的影响在各预设亚组中一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Blood transfusions are commonly administered to patients with acute brain injury. The optimal hemoglobin transfusion threshold is uncertain in this patient population. OBJECTIVE: To assess the impact on neurological outcome of 2 different hemoglobin thresholds to guide red blood cell transfusions in patients with acute brain injury. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, phase 3, parallel-group, investigator-initiated, pragmatic, open-label randomized clinical trial conducted in 72 intensive care units across 22 countries. Eligible patients had traumatic brain injury, aneurysmal subarachnoid hemorrhage, or intracerebral hemorrhage; hemoglobin values below 9 g/dL within the first 10 days after injury; and an expected intensive care unit stay of at least 72 hours. Enrollment occurred between September 1, 2017, and December 31, 2022. The last day of follow-up was June 30, 2023. INTERVENTIONS: Eight hundred fifty patients were randomly assigned to undergo a liberal (transfusion triggered by hemoglobin <9 g/dL; n = 408) or a restrictive (transfusion triggered by hemoglobin <7 g/dL; n = 442) transfusion strategy over a 28-day period. MAIN OUTCOMES AND MEASURES: The primary outcome was occurrence of an unfavorable neurological outcome, defined as a Glasgow Outcome Scale Extended score between 1 and 5, at 180 days following randomization. There were 14 prespecified serious adverse events, including occurrence of cerebral ischemia after randomization. RESULTS: Among 820 patients who completed the trial (mean age, 51 years; 376 [45.9%] women), 806 had available data on the primary outcome, 393 in the liberal strategy group and 413 in the restrictive strategy group. The liberal strategy group received a median of 2 (IQR, 1-3) units of blood, and the restrictive strategy group received a median of 0 (IQR, 0-1) units of blood, with an absolute mean difference of 1.0 unit (95% CI, 0.87-1.12 units). At 180 days after randomization, 246 patients (62.6%) in the liberal strategy group had an unfavorable neurological outcome compared with 300 patients (72.6%) in the restrictive strategy group (absolute difference, -10.0% [95% CI, -16.5% to -3.6%]; adjusted relative risk, 0.86 [95% CI, 0.79-0.94]; P = .002). The effect of the transfusion thresholds on neurological outcome at 180 days was consistent across prespecified subgroups. In the liberal strategy group, 35 (8.8%) of 397 patients had at least 1 cerebral ischemic event compared with 57 (13.5%) of 423 in the restrictive strategy group (relative risk, 0.65 [95% CI, 0.44-0.97]). CONCLUSIONS AND RELEVANCE: Patients with acute brain injury and anemia randomized to a liberal transfusion strategy were less likely to have an unfavorable neurological outcome than those randomized to a restrictive strategy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02968654.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Taccone FS, Rynkowski CB, Møller K, et al. Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial. JAMA. 2024. PMID: 39382241. doi:10.1001/jama.2024.20424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。